Sen Wang
Research Subjects
Sen Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Brandon Carrier
Hooke Laboratories, LLC, Lawrence, USA
1 shared publication - C. J. Cracchiolo
Hooke Laboratories, LLC, Lawrence, USA
1 shared publication - Ethan Sprague
Hooke Laboratories, LLC, Lawrence, USA
1 shared publication - Evelyn Martinez
Hooke Laboratories, LLC, Lawrence, USA
1 shared publication - Gregory Andrew Johnson
Hooke Laboratories, LLC, Lawrence, USA
1 shared publication - Isharat Yusuf
Gossamer Bio, San Diego, USA
1 shared publication
Latest Publications
- Open Access
- 12 July 2023
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-19
Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination
Bruton’s tyrosine kinase (BTK) is an emerging target in multiple sclerosis (MS). Alongside its role in B cell receptor signaling and B cell development, BTK regulates myeloid cell activation and inflammatory responses. Here we demonstrate efficacy of BTK inhibition in a model of secondary progressive autoimmune demyelination in Biozzi mice with experimental autoimmune encephalomyelitis (EAE). We show that late in the course of disease, EAE severity could not be reduced with a potent relapse inhibitor, FTY720 (fingolimod), indicating that disease was relapse-independent. During this same phase of disease, treatment with a BTK inhibitor reduced both EAE severity and demyelination compared to vehicle treatment. Compared to vehicle treatment, late therapeutic BTK inhibition resulted in fewer spinal cord-infiltrating myeloid cells, with lower expression of CD86, pro-IL-1β, CD206, and Iba1, and higher expression of Arg1, in both tissue-resident and infiltrating myeloid cells, suggesting a less inflammatory myeloid cell milieu. These changes were accompanied by decreased spinal cord axonal damage. We show similar efficacy with two small molecule inhibitors, including a novel, highly selective, central nervous system-penetrant BTK inhibitor, GB7208. These results suggest that through lymphoid and myeloid cell regulation, BTK inhibition reduced neurodegeneration and disease progression during secondary progressive EAE.
- 12 July 2023
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-19
Open AccessBruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination
Bruton’s tyrosine kinase (BTK) is an emerging target in multiple sclerosis (MS). Alongside its role in B cell receptor signaling and B cell development, BTK regulates myeloid cell activation and inflammatory responses. Here we demonstrate efficacy of BTK inhibition in a model of secondary progressive autoimmune demyelination in Biozzi mice with experimental autoimmune encephalomyelitis (EAE). We show that late in the course of disease, EAE severity could not be reduced with a potent relapse inhibitor, FTY720 (fingolimod), indicating that disease was relapse-independent. During this same phase of disease, treatment with a BTK inhibitor reduced both EAE severity and demyelination compared to vehicle treatment. Compared to vehicle treatment, late therapeutic BTK inhibition resulted in fewer spinal cord-infiltrating myeloid cells, with lower expression of CD86, pro-IL-1β, CD206, and Iba1, and higher expression of Arg1, in both tissue-resident and infiltrating myeloid cells, suggesting a less inflammatory myeloid cell milieu. These changes were accompanied by decreased spinal cord axonal damage. We show similar efficacy with two small molecule inhibitors, including a novel, highly selective, central nervous system-penetrant BTK inhibitor, GB7208. These results suggest that through lymphoid and myeloid cell regulation, BTK inhibition reduced neurodegeneration and disease progression during secondary progressive EAE.